Previous 10 | Next 10 |
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today provided a corporate update and reported financial results for the third quarter ended September 30...
Alpine Immune Sciences ( NASDAQ: ALPN ) is scheduled to announce Q3 earnings results on Monday, November 14th, after market close. The consensus EPS Estimate is -$0.09 and the consensus Revenue Estimate is $18.68M. Over the last 3 months, EPS estimates have seen 3 up...
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced the company will release third quarter 2022 financial results on Monday, November 14, 2022, a...
- ALPN-303 dose-dependently reduces serum galactose-deficient IgA1 (Gd-IgA1), a pivotal molecule implicated in the pathogenesis of IgA nephropathy (IgAN) - - Data further supports best-in-class profile and initiation of glomerulonephritis (GN) basket clinical trial...
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases will have a poster presentation for ALPN-303’s phase 1 study (RUBY-1) at the upcoming American ...
Summary The recent termination of ALPN-202 trials due to another patient's death caused the share price to plummet. While this was anticipated, I believe that the market has overreacted due to several reasons. The company has enough cash runway to guide them to 2025. ALPN-...
Summary The second patient death prompted Alpine to terminate any future development of davoceticept. It's prudent that Alpine stopped unfruitful developments early on to focus on lower-hanging fruits. Next year, Alpine is poised to run basket studies on ALPN303 which can move...
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases will have poster presentations for ALPN-303 's phase 1 study (RUBY-1) at upcoming scientific conferenc...
Alpine Immune Sciences ( NASDAQ: ALPN ) shed ~9% pre-market Monday after the immunotherapy company announced that it decided to end enrollments in trials for cancer candidate davoceticept (ALPN-202) after a study subject died. Alpine ( ALPN ) was advancing davoceti...
- Company’s primary focus will be the pursuit of expedited development plans for ALPN-303 in multiple autoimmune and inflammatory indications - Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innova...
News, Short Squeeze, Breakout and More Instantly...
Alpine Immune Sciences Inc. Company Name:
ALPN Stock Symbol:
NASDAQ Market:
Alpine Immune Sciences Inc. Website:
FREMONT, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics today announced the election of Mitchell H. Gold, M.D., and Angie You, Ph.D., as independent members of its Board of Directors. Drs. Gold and You are seasoned biotech executives and experienced board members who bring decades...
2024-05-19 02:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2024. On April 10, 2024, Vertex Pharmaceutic...